MyFinsight
Home
Blog
About
Net gain
attributable to common...
-$637K
(99.88%↑ Y/Y)
Net gain
attributable to common...
-$637K
(99.88%↑ Y/Y)
US
$261,572K
(46.80%↑ Y/Y)
Non Us
$2,140K
(-33.56%↓ Y/Y)
Net gain
-$637K
(99.11%↑ Y/Y)
Total revenue
$263,712K
(45.38%↑ Y/Y)
Gain before income
taxes and income tax...
-$614K
(99.14%↑ Y/Y)
Income tax benefit
(expense)
$23K
Income (loss) from
operations
$26,926K
(249.68%↑ Y/Y)
Total costs and
operating expenses
$236,786K
(18.76%↑ Y/Y)
Total other expense,
net
-$27,540K
(48.81%↑ Y/Y)
Interest income
$6,819K
(321.45%↑ Y/Y)
Cost of
services-Molecular Profiling...
$81,328K
(24.51%↑ Y/Y)
General and
administrative expense (see...
$66,548K
(3.39%↑ Y/Y)
Selling and marketing
expense
$53,764K
(27.22%↑ Y/Y)
Research and development
expense
$32,358K
(29.19%↑ Y/Y)
Cost of
services-Pharma Research And...
$2,788K
(16.56%↑ Y/Y)
Other expense, net
-$25,131K
(-37.02%↓ Y/Y)
Interest expense
$9,228K
(-51.96%↓ Y/Y)
Back
Back
Income Statement
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
source: myfinsight.com